Journal of Pharmacy and Pharmaceutical Sciences

Papers
(The H4-Index of Journal of Pharmacy and Pharmaceutical Sciences is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Evaluating the Effects of Agomelatine on Polysomnography Parameters in Patients with Obstructive Sleep Apnea.80
Comparing broad and narrow phenotype algorithms: differences in performance characteristics and immortal time incurred59
Effect of Oregon grape root extracts on P-glycoprotein mediated transport in in vitro cell lines54
Corrigendum: Applications of exhaled breath condensate analysis for drug monitoring and bioequivalence study of inhaled drugs47
Therapeutic update on oral potassium exchange resin use in chronic kidney disease patients: a systematic review of randomized controlled clinical trials42
Drug-disease interaction: Clinical consequences of inflammation on drugs action and disposition27
Monkeypox: Virology, Pathophysiology, Clinical Characteristics, Epidemiology, Vaccines, Diagnosis, and Treatments18
Effect of Concomitant Drug Use on the Onset and Exacerbation of Diabetes Mellitus in Everolimus-Treated Cancer17
Network pharmacology and molecular docking reveal the immunomodulatory mechanism of rhubarb peony decoction for the treatment of ulcerative colitis and irritable bowel syndrome16
Requirements for Additional Strength Biowaivers for Modified Release Solid Oral Dosage Forms in International Pharmaceutical Regulators Programme Participating Regulators and Organisations: Difference16
Applications of Exhaled Breath Condensate Analysis for Drug Monitoring and Bioequivalence Study of Inhaled Drugs15
Post-Marketing Safety of Vemurafenib: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System15
A Legislative/Legal History of Prescription Drug Advertising and Promotion Regulation14
Expanding the eligibility criteria for drugs in Canada’s time-limited health technology assessment and temporary drug access processes will further accelerate access to new medicines14
Forkhead box O1 transcription factor; a therapeutic target for diabetic cardiomyopathy14
0.070131063461304